Results 261 to 270 of about 29,857,715 (400)
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Correction: Metric-based vs peer-reviewed evaluation of a research output: Lesson learnt from UK's national research assessment exercise. [PDF]
Koya K, Chowdhury G.
europepmc +1 more source
Researches on Resource Assessment in the Branch of Resource Analysis of U.S.G.S. : Recent Trends
Ryoichi Kouda
openalex +2 more sources
Research assessment using early citation information
Stephan B. Bruns, D. Stern
semanticscholar +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Metric-based vs peer-reviewed evaluation of a research output: Lesson learnt from UK's national research assessment exercise. [PDF]
Koya K, Chowdhury G.
europepmc +1 more source
How should research be organised? An alternative to the UK Research Assessment Exercise [PDF]
Gillies, D.
core
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski+19 more
wiley +1 more source